83 FR 54604 - Meeting of the National Advisory Council on Nurse Education and Practice

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration

Federal Register Volume 83, Issue 210 (October 30, 2018)

Page Range		54604-54604
FR Document		2018-23685

The National Advisory Council on Nurse Education and Practice (NACNEP or the Council) has scheduled a public meeting. Information about NACNEP and the agenda for this meeting can be found on the NACNEP website at https://www.hrsa.gov/advisory-committees/nursing/index.html.

Federal Register, Volume 83 Issue 210 (Tuesday, October 30, 2018)

[Federal Register Volume 83, Number 210 (Tuesday, October 30, 2018)]
[Notices]
[Page 54604]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-23685]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration


Meeting of the National Advisory Council on Nurse Education and 
Practice

AGENCY: Health Resources and Services Administration (HRSA), Department 
of Health and Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Advisory Council on Nurse Education and Practice 
(NACNEP or the Council) has scheduled a public meeting. Information 
about NACNEP and the agenda for this meeting can be found on the NACNEP 
website at https://www.hrsa.gov/advisory-committees/nursing/index.html.

DATES: November 19, 2018, 8:30 a.m.-4:15 p.m. ET.

ADDRESSES: This meeting will be held by teleconference and webinar. The 
conference call-in number is 1-888-455-0640; passcode: HRSA COUNCIL. 
The webinar link is https://hrsa.connectsolutions.com/nacnep/.

FOR FURTHER INFORMATION CONTACT: Tracy L. Gray, MBA, MS, RN, Division 
of Nursing and Public Health, Bureau of Health Workforce, HRSA, 5600 
Fishers Lane, 11N112, Rockville, Maryland 20857; 301-443-3346; or 
[email protected].

SUPPLEMENTARY INFORMATION: NACNEP provides advice and recommendations 
to the Secretary of Health and Human Services (Secretary) and the U.S. 
Congress on policy matters arising in the administration of Title VIII 
of the Public Health Service (PHS) Act, as amended, including the range 
of issues relating to nurse supply, education, and practice 
improvements. NACNEP provides an annual report to the Secretary and 
Congress describing the activities of NACNEP, including findings and 
recommendations made by NACNEP concerning the activities under this 
title.
    During the November 19, 2018, meeting, NACNEP will continue 
discussing areas where nursing can take the lead in the transition of 
the health care system to value-based care through improvements to 
nurse education and practice, to advance the development of its 15th 
Report. In addition, the members will discuss strategic priorities and 
future directions for the Council and discuss possible topics for its 
16th Report. Agenda items are subject to change as priorities dictate. 
Refer to the NACNEP website for any updated information concerning the 
meeting.
    Members of the public will have the opportunity to provide 
comments. Public participants may submit written statements in advance 
of the scheduled meeting. Oral comments will be honored in the order 
they are requested and may be limited as time allows. Requests to make 
oral comments or provide written statements to NACNEP should be sent to 
Ms. Tracy L. Gray, Designated Federal Official, using the contact 
information above at least 3 business days prior to the meeting.

Amy P. McNulty,
Acting Director, Division of the Executive Secretariat.
[FR Doc. 2018-23685 Filed 10-29-18; 8:45 am]
 BILLING CODE 4165-15-P

54604 Federal Register / Vol. 83, No. 210 / Tuesday, October 30, 2018 / Notices

* 4. Proposed labeling for oxycodone HCl IR advisory-committees/nursing/ DEPARTMENT OF HEALTH AND
capsules, PMRS, NDA 209155 (Dec. index.html. HUMAN SERVICES
2017).
* 5. Complete Response letter, NDA 209155 DATES: November 19, 2018, 8:30 a.m.– National Institutes of Health
(November 16, 2017). 4:15 p.m. ET.
* 6. ‘‘Filing Communication Responses,’’ ADDRESSES: This meeting will be held Government-Owned Inventions;
PMRS, NDA 209155. by teleconference and webinar. The Availability for Licensing
* 7. ‘‘Request for Priority Review
Designation,’’ PMRS, NDA 209155.
conference call-in number is 1–888–
455–0640; passcode: HRSA COUNCIL. AGENCY: National Institutes of Health,
* 8. ‘‘Memorandum of Meeting Minutes’’ for HHS.
Type B, Pre-NDA, July 11, 2016 The webinar link is https://
teleconference (August, 8, 2016). hrsa.connectsolutions.com/nacnep/. ACTION: Notice.
* 9. ‘‘NDA 209155 CMC Information Request FOR FURTHER INFORMATION CONTACT:
5–25–17,’’ PMRS, NDA 209155. Tracy L. Gray, MBA, MS, RN, Division SUMMARY: The invention listed below is
* 10. Centers for Disease Control, ‘‘Integrated
of Nursing and Public Health, Bureau of jointly owned by an agency of the U.S.
Prevention Services for HIV Infection, Government with Pontificia
Viral Hepatitis, Sexually Transmitted Health Workforce, HRSA, 5600 Fishers
Lane, 11N112, Rockville, Maryland Universidad Catolica de Chile and is
Diseases, and Tuberculosis for Persons available for licensing to achieve
Who Use Drugs Illicitly: Summary 20857; 301–443–3346; or DScott1@
hrsa.gov. expeditious commercialization of
Guidance From the CDC and the U.S.
Department of Health and Human
results of federally-funded research and
Services,’’ Morbidity and Mortality
SUPPLEMENTARY INFORMATION: NACNEP development. Foreign patent
Weekly Report, vol. 61, pp. 1–40, 2012. provides advice and recommendations applications are filed on selected
* 11. National Institute on Drug Abuse, to the Secretary of Health and Human inventions to extend market coverage
‘‘What is heroin and how is it used?’’, Services (Secretary) and the U.S. for companies and may also be available
available at https://www.drugabuse.gov/ Congress on policy matters arising in for licensing.
publications/research-reports/heroin/ the administration of Title VIII of the FOR FURTHER INFORMATION CONTACT:
what-heroin (accessed June 13, 2018). Public Health Service (PHS) Act, as
* 12. FDA News Release, ‘‘FDA requests Licensing information and copies of the
amended, including the range of issues U.S. patent application listed below
removal of Opana ER for risks related to relating to nurse supply, education, and
abuse’’ (June 8, 2017), available at may be obtained by communicating
https://www.fda.gov/NewsEvents/
practice improvements. NACNEP with Ami Gadhia, JD, LL.M., CLP,
Newsroom/PressAnnouncements/ provides an annual report to the Technology Transfer and Patenting
ucm562401.htm. Secretary and Congress describing the Specialist, National Center for
13. Hunt, R. et al., ‘‘A Mechanistic activities of NACNEP, including Advancing Translational Sciences, NIH,
Investigation of Thrombotic findings and recommendations made by 9800 Medical Center Drive, Rockville,
Microangiopathy Associated with IV NACNEP concerning the activities
Abuse of Opana ER,’’ Blood, Feb. 16,
MD 20850, Phone: 301–217–6098, or
under this title. email ami.gadhia@nih.gov. A signed
2017. During the November 19, 2018,
* 14. FDA Guidance for Industry ‘‘Abuse- Confidential Disclosure Agreement will
meeting, NACNEP will continue be required to receive copies of
Deterrent Opioids—Evaluation and
Labeling,’’ available at https:// discussing areas where nursing can take unpublished patent applications.
www.fda.gov/downloads/Drugs/ the lead in the transition of the health
SUPPLEMENTARY INFORMATION:
Guidances/UCM334743.pdf. care system to value-based care through
improvements to nurse education and Technology description follows.
Dated: October 25, 2018. c-Abl Tyrosine Kinase Inhibitory
practice, to advance the development of
Denise Hinton, Compounds and Methods of
its 15th Report. In addition, the
Chief Scientist. members will discuss strategic priorities Manufacture and Use
[FR Doc. 2018–23710 Filed 10–29–18; 8:45 am] and future directions for the Council Description of Technology
BILLING CODE 4164–01–P and discuss possible topics for its 16th
Report. Agenda items are subject to The invention includes compounds
change as priorities dictate. Refer to the that inhibit c-Abl tyrosine kinase, and
DEPARTMENT OF HEALTH AND NACNEP website for any updated methods of making them which include
HUMAN SERVICES information concerning the meeting. administering (i) a therapeutically
Members of the public will have the effective amount of the compound or a
Health Resources and Services stereoisomer, tautomer,
Administration opportunity to provide comments.
Public participants may submit written pharmaceutically acceptable salt,
statements in advance of the scheduled solvate, or prodrug thereof; or (ii) a
Meeting of the National Advisory therapeutically effective amount of the
Council on Nurse Education and meeting. Oral comments will be
honored in the order they are requested pharmaceutical compositions to a
Practice patient with the disease which involves
and may be limited as time allows.
AGENCY: Health Resources and Services Requests to make oral comments or c-Abl tyrosine kinase, including the
Administration (HRSA), Department of provide written statements to NACNEP overexpression of it. In some
Health and Human Services (HHS). should be sent to Ms. Tracy L. Gray, embodiments, the compound inhibits c-
ACTION: Notice. Designated Federal Official, using the Abl tyrosine kinase by binding to an
allosteric site of the c-Abl tyrosine
khammond on DSK30JT082PROD with NOTICES

contact information above at least 3
SUMMARY: The National Advisory business days prior to the meeting. kinase. In some embodiments, the
Council on Nurse Education and compound binds to a myristate pocket
Practice (NACNEP or the Council) has Amy P. McNulty, of the c-Abl tyrosine kinase.
scheduled a public meeting. Information Acting Director, Division of the Executive This technology is available for
about NACNEP and the agenda for this Secretariat. licensing for commercial development
meeting can be found on the NACNEP [FR Doc. 2018–23685 Filed 10–29–18; 8:45 am] in accordance with 35 U.S.C. 209 and 37
website at https://www.hrsa.gov/ BILLING CODE 4165–15–P CFR part 404, as well as for further

VerDate Sep<11>2014 17:34 Oct 29, 2018 Jkt 247001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 E:\FR\FM\30OCN1.SGM 30OCN1

Document Created: 2018-10-30 00:43:08
Document Modified: 2018-10-30 00:43:08

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Dates		November 19, 2018, 8:30 a.m.-4:15 p.m. ET.
Contact		Tracy L. Gray, MBA, MS, RN, Division of Nursing and Public Health, Bureau of Health Workforce, HRSA, 5600 Fishers Lane, 11N112, Rockville, Maryland 20857; 301-443-3346; or [email protected]
FR Citation		83 FR 54604

83 FR 54604 - Meeting of the National Advisory Council on Nurse Education and Practice

DEPARTMENT OF HEALTH AND HUMAN SERVICESHealth Resources and Services Administration

Federal Register Volume 83, Issue 210 (October 30, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration